Ozempic maker Novo Nordisk denies flooding market with 'junk' patents after FTC challengeByBruce GilPublishedMay 2, 2024
Wegovy sales more than doubled as the weight loss drug boom keeps powering Novo NordiskByBruce GilUpdatedMay 2, 2024
Ozempic is so hot right now that subsidies for the drug are being cut in Novo Nordisk's home countryByBruce GilUpdatedMay 1, 2024
Johnson & Johnson wants to pay $6.5 billion to settle its talc ovarian cancer lawsuitsByBruce GilPublishedMay 1, 2024
Novo Nordisk earnings are coming during a weight loss drugs sales surge. Here are 3 things to watchByBruce GilUpdatedMay 1, 2024
Ozempic and 19 other drugs have 'junk' patents, the FTC says in a new challengeByBruce GilUpdatedApril 30, 2024
Weight loss drugs are so hot that Eli Lilly is expecting $2 billion more in sales this yearByBruce GilPublishedApril 30, 2024
Some of the popular weight loss drug Wegovy is back on shelves after a shortage, the FDA saysByBruce GilUpdatedApril 29, 2024
Philips settled a breathing machine recall case and it sent the stock soaringByBruce GilUpdatedApril 29, 2024
These lifestyle gyms aren't competing with Ozempic — they're embracing itByBruce GilPublishedApril 28, 2024
Bird flu traces have been found in cows' milk. Should we be worried?ByBruce GilPublishedApril 26, 2024
AbbVie's newer drugs are offsetting losses of the world's once best-selling medicationByBruce GilPublishedApril 26, 2024
Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundupByBruce GilPublishedApril 26, 2024
Merck and Bristol-Myers Squibb are bracing to lose their most lucrative patentsByBruce GilUpdatedApril 25, 2024
Drug sales keep beating Wall Street's expectations and boosting some pharma stocksByBruce GilPublishedApril 25, 2024
